Dr. Naoto Hirano
Dr. Naoto Hirano
Contact
Dr. Naoto Hirano
Senior Investigator

Naoto.Hirano@uhnresearch.ca

Senior Investigator

Dr. Naoto Hirano’s research program aims to devise novel anti-tumor immunotherapeutic modalities that can cure cancer. Dr. Hirano’s research team is particularly interested in understanding how the interactions between T cells and antigen-presenting cells affect priming, expansion, persistence and differentiation of T cells, as well as how this leads to the subsequent generation and maintenance of anti-tumor T cell memory.

Experience & Education
  • Clinician Scientist I, OICR
  • Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Current Affiliations
  • Senior Investigator, OICR
  • Associate Director for Research, Tumour Immunotherapy Program, Princess Margaret Cancer Centre
  • Senior Scientist, Princess Margaret Cancer Centre
  • Professor of Medicine, Department of Immunology, University of Toronto
Select Publications

See Dr. Hirano’s recent publications on PubMed.

Research Areas
Treatment
Disease Areas
Melanoma
Opportunities to Collaborate

To collaborate with Dr. Hirano, please contact him directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

In the News
Research breakthrough paves way for more cancer patients to benefit from immunotherapy, regardless of ancestry
Research breakthrough paves way for more cancer patients to benefit from immunotherapy, regardless of ancestry
Mar 01, 2021
OICR-affiliated researchers awarded $6.6 million in funding from CIHR
OICR-affiliated researchers awarded $6.6 million in funding from CIHR
Mar 09, 2021